Avid Bioservices Inc (CDMO)

[entdoc]

FtM, great posts as usual. It's more informative now here on this board than med school thanks to you and so many others. Agree anti CD47 is interesting. Deja vu all over again? My sense of it is that solid cancers and/or their metastases that are large enough to kill and not surgically resectable are not going to be materially diminished by immune-enhancing MABs, at least in the near future. Earlier detection methods, which involve cost-effective screening, and earlier treatment seems a perfect application for these agents. And what could be better than an MAB that "detects" small tumors, "tags" them for imaging and for follow-up, and "treats" them...all at once? That's Bavituximab. The other undeniable reality for those who have been in experimental medicine is this: If an agent is bioactive, anti-inflammatory or ant-neoplastic AND proven safe, it will probably have an application. Keep using it in the clinic long enough and another possibly more important secondary indication for its use will be found. The spin-offs from clinical research are often more valuable than primary targets.